Keytruda

GSK/Merck KGgA cancer drug fails in third trial

It has been bad year for bintrafusp alfa; it rang in the New Year glumly with news that it had failed to beat Merck/MSD’s Keytruda in non-small cell

Aspirin to be trialled as part of new treatment for triple negative breast cancer

Earlier this year, Merck &Co immunotherapy treatment Keytruda (pembrolizumab) demonstrated significant and meaningful improvement in its phase 3 trial, meeting its end-point of event-free survival (EFS) for the treatment

Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’

Elsewhere in its Q2 results, Merck saw sales growth for its blockbuster immunotherapy Keytruda, which grew by 23% to $4.2bn, reflecting continued demand in the major non-small cell lung

Merck, Eisai’s Keytruda/Lenvima regimen scores full approval in endometrial cancer

Keytruda plus Lenvima was previously approved under the FDA’s accelerated approval process. ... The Keytruda plus Lenvima was previously approved under the FDA’s accelerated approval process for the treatment of certain endometrial cancer patients.

Keytruda scores a win in treating early-stage breast cancer pre- and post-surgery

Merck &Co – known as MSD outside the US and Canada – has highlighted new data for its blockbuster immunotherapy Keytruda used before and after surgery in high-risk, early-stage triple negative ... Now, Merck has additional data to make its case for

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]